1-9-2015

Associations between Butylparaben and Thyroid Levels in Females Aged 12 and over (NHANES, 2007-2008)

Andrea H. Decker

Follow this and additional works at: http://scholarworks.gsu.edu/iph_theses

Recommended Citation
http://scholarworks.gsu.edu/iph_theses/370

This Thesis is brought to you for free and open access by the School of Public Health at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Public Health Theses by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact scholarworks@gsu.edu.
Associations between Butylparaben and Thyroid Levels in Females aged 12 and over (NHANES, 2007-2008)

Andrea Harlow Decker

Master of Public Health

Georgia State University
School of Public Health
Associations between Butylparaben and Thyroid Levels in Females aged 12 and over (NHANES, 2007-2008)

by

Andrea Decker

Approved:

____________________________________
Christine Stauber, Ph.D., M.S.
Committee Chair

____________________________________
Scott Weaver, Ph.D.

____________________________________
Date
Author’s Statement

In presenting this thesis as a partial fulfillment of the requirements for an advanced degree from Georgia State University, I agree that the Library of the University shall make it available for inspection and circulation in accordance with its regulations governing materials of this type. I agree that permission to quote from, to copy from, or to publish this thesis may be granted by the author or, in his/her absence, by the professor under whose direction it was written, or in his/her absence, by the Associate Dean, College of Health and Human Sciences. Such quoting, copying, or publishing must be solely for scholarly purposes and will not involve potential financial gain. It is understood that any copying from or publication of this thesis which involves potential financial gain will not be allowed without written permission of the author.

Andrea Harlow Decker

Signature of Author
Acknowledgements

I would like to thank my family for being so supportive during my educational career, helping me get past the tough times and reaching my goals. I would also like to acknowledge the wonderful Public Health staff and faculty of Georgia State University. Special thanks to my thesis committee: Dr. Christine Stauber and Dr. Scott Weaver, I appreciate their support.
Notice to Borrowers Page

All theses deposited in the Georgia State University Library must be used in accordance with the stipulations prescribed by the author in the preceding statement.

The author of this thesis is:

**Andrea Harlow Decker**
100 Brookstone Park
Newnan, GA 30265

The Chair of the committee for this thesis is:

**Dr. Christine Stauber**
Institute of Public Health
414 Petit Science Center
100 Piedmont Avenue, NE
Atlanta, GA 30302

Georgia State University
P.O. Box 3995
Atlanta, Georgia 30302-3995

Users of this thesis who not regularly enrolled as students at Georgia State University are required to attest acceptance of the preceding stipulation by signing below. Libraries borrowing this thesis for the use of their patrons are required to see that each user records here the

<table>
<thead>
<tr>
<th>Name of User</th>
<th>Address</th>
<th>Date</th>
<th>Type of Use (Examination Only or Copying)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Curriculum Vitae

Andrea Harlow Decker

100 Brookstone Park
Newnan, GA 30265
(678) 301-9147
adecker89@hotmail.com

Education

Master of Public Health (Epidemiology)  Expected graduation December 2014
• Georgia State University; GPA: 3.93

Bachelor of Science in Health Education (Community Health)  Graduated August 2012
• Georgia College and State University; GPA: 3.61 (institution GPA)

Public Health Experience

Public Health Practicum  Healthcare Georgia Foundation  May 2014- October 2014
• “Two Georgia’s” Initiative: Researching disparities associated with rurality.
• Researching and constructing questionnaire questions for rural healthcare survey.

Community Health Intern  Communities In Schools, Milledgeville  May 2012-August 2012
• Redesigning the curriculum for the Scrubby Bear program, a part of the Red Cross.
• Designing and promoting community health through projects and presentations.

Relevant Epidemiology Courses: Infectious Disease Epidemiology, STD/HIV Epidemiology, Principles of Tobacco Control, Public Health Policy, and Case Studies in Epidemiology.

Employment

Assistant Swim Coach  Coweta County School System: Northgate High School  October 2012- Present
Student Assistant  Center for Student Success: GCSU  January 2012- May 2012
Resident Assistant  Darton College Commons Dorms  August 2009- May 2010
Assistant Swim Coach and Lifeguard  Summit Family YMCA  October 2004-August 2008 and Summers

Additional Experience and Awards

• Golden Key International Honour Society Member: Georgia State University Alpha Chapter
• Public Health Student Organization: Georgia College and State University
• The Honors Program of Darton College: Scholar Award
• Chair member of the Scrubby Bear (Red Cross) program at Georgia College and State University

Skills
• Microsoft Office, SAS
Abstract

Background: Paraben exposure occurs everyday to most people unknowingly. Parabens are present in most personal care products in varying amounts. Presently, parabens are not listed as endocrine disruptors; however, some research has shown parabens associated with decreases in thyroid hormone levels. The chemical and adsorption mechanism for parabens in association with thyroid hormones is not well understood. Determining whether parabens are associated with a change in thyroid hormone levels can help reduce the incidence of possible adverse health effects with exposure to parabens.

Methodology: The selected study variables were analyzed using SAS version 9.2. Data were obtained from the 2007-2008 National Health and Nutrition Examination Survey (NHANES). Analyses were performed separately for adolescent females (12-19) and adult females (20+). Weighted means were performed for the main independent and dependent variables of interest stratified by race/ethnicity groups and by smoking status. Independent samples t-test and ANOVA was used to test significance of differences of weighted means. Weighted bivariate linear regression was performed for each dependent variable (Thyroid Stimulating Hormone [TSH], Triiodothyronine [T3], and Thyroxine [T4]) regressed on butylparaben. Weighted multiple linear regressions were performed and parameter estimates with 95% confidence intervals were used to ascertain the measure of effect. Separate regression models stratified by age group (adolescent vs. adult) were ran for each dependent variable (TSH, T3, and T4) regressed on butylparaben level and covariates, race/ethnicity and smoking status (ever smoked).

Results: Weighted bivariate linear regression showed that among adult females, for each ng/ml increase in butylparaben, there was a -1.07 decrease in ng/dL T3 (p< .05) levels. Among adult females, for each ng/ml increase in butylparaben was associated with a -0.12 decrease in ug/dL T4 (p< .01) levels. Butylparaben was not predictive of TSH (p=. 15), T3 (p=. 79), or T4 (p=. 07) levels in adolescent females, whereas butylparaben in adult females was not predictive of TSH (p=. 55) levels.

Weighted multiple linear regression showed higher butylparaben levels among adult females were associated with 0.12 ug/dL lower than average T4 levels (p<. 01) controlling for race/ethnicity and smoking status; however, no association was found among adolescent females. Mexican American adult females had 0.17mIU/L lower than average TSH levels compared to other race adult females (p<.001), whereas, other Hispanic adolescent females had 0.3 mIU/L higher than normal TSH levels compared to other race adolescent females (p<. 05) and other Hispanic adult females had 0.12mIU/L higher TSH levels compared to other race adult females (p<. 05), controlling for butylparaben and smoking status. Other Hispanic adult females showed 0.03 ng/dL lower than average T3 levels compared to other race adult females (p<. 05) whereas other Hispanic adolescent females showed
0.67 ug/dL lower than average T4 levels compared to other race adolescent females (p< .0001), controlling for butylparaben and smoking status. Non-Hispanic Black female adolescents had 0.44 ug/dL higher than average T4 levels compared to other race adolescent females (p< .05) whereas non-Hispanic black adults showed a 0.28 ug/dL higher than average T4 levels compared to other race adult females (p=. 05), controlling for butylparaben and smoking status. Ever smoking status was not associated with any of the thyroid hormone measures.

**Conclusion:** While parabens are currently not considered endocrine disruptors, the human metabolism of and effects from exposure to parabens are not well understood. Results from this study showing decreased levels of some thyroid hormone levels (TSH, T3, and T4) associated with increased levels of butylparaben was found, as well as differences in thyroid hormone levels among racial/ethnic groups. Although not many human studies have found significant results, some rodent studies have found butylparaben associations with thyroid hormone changes. The results of this study indicating no statistically significant association between butylparaben and decreases in thyroid hormone levels are consistent with results of some rodent studies. In light of these findings, additional human studies with paraben exposure and thyroid hormone levels are needed to increase knowledge of the mechanism and effect of parabens in the human body.

**Key Words:** Butylparaben, Thyroid Stimulating Hormone (TSH), Triiodothyronine (T3), Thyroxine (T4), NHANES, Female, Cross-sectional, Ever Smoking, Race/Ethnicity.
Table of Contents

Abstract ............................................................................................................................................... 6-7

List of Tables and Figures ................................................................................................................. 10

Chapter I Introduction

1a. Background ...................................................................................................................................... 11

1b. Purpose of Study .............................................................................................................................. 11-12

1c. Hypothesis ........................................................................................................................................ 12

Chapter II Literature Review

2a. Overview of Parabens ...................................................................................................................... 13

2b. Legislations of Parabens ................................................................................................................. 13-14

2c. Exposure to Parabens ...................................................................................................................... 14

2d. Metabolism of Parabens in Humans ............................................................................................. 15-16

2e. Endocrine System ........................................................................................................................... 16-17

2f. Triiodothyronine (T3) ...................................................................................................................... 17

2g. Thyroxine (T4) ............................................................................................................................... 17

2h. Thyroid-Stimulating Hormone (TSH) ........................................................................................... 17

2i. Endocrine Disruption ...................................................................................................................... 18-19

2j. Estrogenic Effects of Parabens ....................................................................................................... 19-20

2k. Smoking ......................................................................................................................................... 20

Chapter III Methodology

3a. Data Source ...................................................................................................................................... 21

3b. Study Population ............................................................................................................................. 21-22

3c. Data Analysis ................................................................................................................................... 23
Chapter IV Results

4a. Sample Demographics ........................................................................................................... 24
4b. Descriptive Statistics ........................................................................................................... 25-28
4c. Bivariate Analysis ............................................................................................................... 28-29
4d. Multivariate Analysis .......................................................................................................... 29-32

Chapter V Discussion and Conclusion

5a. Discussion .......................................................................................................................... 33-34
5b. Strengths ........................................................................................................................... 35
5c. Limitations .......................................................................................................................... 35
5d. Future Study ...................................................................................................................... 35-36
5e. Conclusion .......................................................................................................................... 36

References .................................................................................................................................. 37-41

Appendices .................................................................................................................................. 42-44
List of Tables and Figures

Figure 1: Basic Paraben Chemical Structure ................................................................. 3
Figure 2: Butylparaben Chemical Structure ................................................................. 3
Figure 3: Parabens Exposure and Metabolism Pathways ............................................... 6
Figure 4: Release and Flow of TSH, T3, and T4 Hormones. Adapted from Faix & Thienpont 2013 ................................................................. 8
Figure 5: Inclusion and Exclusion Subsample Flow Chart ........................................... 12
Table 1: Distribution of Race/Ethnicity in Adolescent and Adult Females .................... 14
Table 2: Distribution of Race/Ethnicity in Butylparaben and Thyroid Hormone Subgroups Among Adolescent and Adult Females ........................................... 14
Table 3: Weighted Means of Butylparaben, TSH, T3, and T4 for Adolescent and Adult Females by Race/Ethnicity Groups ......................................................... 15
Table 4: Weighted Means of Butylparaben, TSH, T3, and T4 for Adolescent and Adults Female Smokers and Non-Smokers ......................................................... 16
Table 5: Weighted Regression of TSH, T3, and T4 on Butylparaben for Adolescent and Adult Females ......................................................... 16
Table 6: Weighted Regression of TSH (log mIU/L) on Butylparaben (log ng/ml) and Covariates ......................................................... 17
Table 7: Weighted Regression of T3 (ng/dL) on Butylparaben (log ng/ml) and Covariates ......................................................... 18
Table 8: Weighted Regression of T4 (ug/dL) on Butylparaben (log ng/ml) and Covariates ......................................................... 19

Appendices:

Table 9: Parabens and Synonymous Names ................................................................. 29
Table 10: Trimester Specific T3, T4, and TSH Hormone Ranged During Pregnancy ......... 30
Table 11: Butylparaben Studies with Estrogenic Results ............................................. 31
Chapter I
Introduction

1a. Background

Parabens, widely used for their antibacterial properties, are found in many personal care products. Parabens are an ester of parahydroxybenzoic acid. It is believed that the pharmaceutical industry first used parabens as preservatives in the 1920s. Over the decades since its introduction, parabens have found their way into many products used daily such as cosmetics, hair products, lotions, shaving products, etc. Parabens are sometimes used in food and drink products, especially canned goods, to help preserve the product and create a longer shelf life.

Starting in the early 1990s the fear of possible endocrine disrupting powers of parabens began, due to articles suggesting negative health effects from pesticides and other man-made chemicals.\textsuperscript{1-4} In vivo and in vitro studies soon followed; an overview of these studies will be covered in the literature review. To date, it is uncertain whether or not parabens cause endocrine disruption in humans. Many rodent studies have shown estrogenic tendencies, whereas some others have shown small to no estrogenic effect.\textsuperscript{5-9} Few human paraben studies have been completed,\textsuperscript{10-12} also with conflicting results.

A small number of natural or chemical compounds have been scientifically proven to create endocrine disruption including, diethylstilbestrol (DES), dioxin, polychlorinated biphenyls (PCBs), DDT, and some other pesticides.\textsuperscript{13} Endocrine disruption causes interference with the normal functioning of the endocrine system. Thyroid hormones, which control many bodily functions including growth, development, and reproduction, are very important to human homeostasis. Thyroid hormones are also incredibly important for fetus and child development, without which could cause detrimental developmental effects. The long-term, low-dose effect of paraben exposure is not known, nor has it been studied, thus the risk for negative human health effects is unknown.\textsuperscript{14}

1b. Purpose of Study

The purpose of this study was to examine the association between butylparaben exposure and thyroid function in females age 12 and over, in a nationally representative, human population. This topic is important to public health because of the everyday use of products that contain parabens such as cosmetics and foods. Past studies have shown parabens associated with breast cancer as well as damage to sperm cells. The Cosmetic Ingredient Review Expert Panel (CIR) concluded that parabens are safe as cosmetic ingredients. However the anti-paraben movement has recently led many cosmetic companies to remove parabens from their products. Overall, increasing the knowledge of the scientific community on the possible harmful effects of parabens is the main objective of my study. In order to more fully examine the role of parabens in relation to thyroid
levels this study aims to use a nationally representative dataset to show the association of urine paraben levels with blood thyroid levels.

1c. Hypothesis

H1: Butylparaben will be associated with decreases in thyroid hormone levels (TSH, T3, and T4).
H0: Butylparaben will not be associated with decreases in thyroid hormone levels (TSH, T3, and T4).

This study examined the research question of whether butylparaben levels in urine was associated with blood thyroid hormone levels (TSH, T3, and T4) in females aged 12 and over in the National Health and Nutrition Survey from 2007-2008. Specifically, the central hypothesis of this study is that butylparaben will cause thyroid hormone levels to decrease. Previous studies showed that analyzing data among two separate age groups, adolescents aged 12-19 and adults age 20 and over, was warranted due to differing thyroid activity among age groups. The results of some studies suggest that parabens might be thyroid hormone receptor agonists. Ever smoking and race/ethnicity were controlled for in the analyses; women who were pregnant, taking birth control, and who had thyroid problems were excluded from the study due to differing levels of thyroid hormones caused by each factor. Race/ethnicity was adjusted for when estimating the association between butylparaben and thyroid hormone levels.
Chapter II
Literature Review

The literature review contains compiled research from various studies on paraben exposure and thyroid levels as well as the estrogenic and endocrine disrupting effects of parabens. This review also is composed of an overview of parabens, the endocrine system, and thyroid hormones. The literature review is designed to help understand parabens, how they work, and what effects they have on human health.

2a. Overview of Parabens

Parabens are man-made chemicals that are considered esters of p-hydroxybenzoic acid. Parabens are one of the most commonly used preservatives in personal care products, foods, beverages, and pharmaceuticals. Parabens are readily used throughout the world due to their low cost and low toxicity. Methylparaben, propylparaben, and butylparaben are the most frequently used in personal care products. The use of more than one paraben or similar preservative within a product is common practice. With the use of multiple preservatives smaller doses can be used while increasing the preservative effect. Preservatives, such as parabens, are used in products to prevent growth of microbials and to maintain the integrity of the product. The first usage of parabens date back to 1920 when the pharmaceutical industry used them as preservatives. The chemical structures of a basic paraben as well as butylparaben, the main paraben of interest for this study, are shown in Figures 1 and 2.

2b. Legislation of Parabens

In the United States, parabens are not widely legislated. The Food and Drug Administration (FDA) does not regulate ingredients in cosmetics, where a majority of parabens can be found. Color additives are the only ingredient that may be regulated by the FDA under The Federal Food, Drug, and Cosmetic Act (FD&C Act). In comparison, many other countries, including the European Union (EU) countries and Japan, have limits on the amount by mass of parabens allowed in cosmetic products: 0.4% for a single paraben and 0.8% for multiple parabens in EU countries, and 1.0% total paraben concentration in Japan. Increasing concern about endocrine disruption from man-made chemicals has lead to a review of the toxicity of parabens. The Cosmetic Ingredient Review expert panel examined the safety assessment of parabens in 2008. After reviewing hundreds of references on parabens the panel concluded that parabens are safe to use. The panel set no-observed adverse
effect levels (NOAEL’s) at 1.2mg/kg bw/day for adults and 0.3mg/kg bw/day for infants. In the European Union the Scientific Committee on Consumer Products (SCCP) concluded that methylparaben and ethylparaben are safe for use in cosmetics at up to 0.4% of the cosmetic concentration, with an acceptable daily intake (ADI) set at 10mg/kg bw/day. Insufficient results were found for propyl-, isopropyl-, butyl-, and isobutylparaben, with no ADI set for these parabens. Butylparaben is not safe to be used in food products according to data collected by the WHO. Examining the regulation that other countries have placed on parabens in comparison to the United States, there is a need for product review programs to regulate parabens being used for human consumption. A sign of hope for paraben regulation is the formation of the United States Endocrine Disruptor Screening and Testing Advisory Committee (EDSTAC).

2c. Exposure to Parabens

The most common exposure to parabens is through personal care products including but not limited to: makeup, moisturizers, hair-care products, shaving creams, pharmaceuticals, foods, drinks. A 1995 study by Rastogi et al. analyzed 215 cosmetic products and found that 77% of rinse-off products contained parabens, while 99% of leave-on products contained parabens. Dodson et al. completed a study which tested 213 products for parabens; parabens were found in 10 products, 7 of which were from products where parabens were not found on the label. A study done by Rastogi found that 45% of skin creams were incorrectly labeled, while 10% of other products were mislabeled with respect to parabens. Retail cosmetics must declare ingredients on the packaging of the product, which helps to determine which products contain parabens. In Appendix 1 is a list of names used for each paraben.

Humans are exposed to parabens via three routes: dermal, inhalation, and ingestion. The majority of personal care products enter the body through dermal exposure. While food and drink are the main sources of ingestion and air (and dust) is the main route for inhalation exposure, presumably from personal care product usage. The amount of parabens found in indoor air and dust vary regionally, most likely due to differing consumption of paraben containing personal care products. Parabens have also been found in ground water as well as waste water treatment facilities, most likely caused by run-off from daily usage of parabens. Daily estimates of paraben usage from cosmetic products for adults is 17.76g and 0.378g for infants, calculated by Błędzka, et al. from Cosmetic Ingredient Review panel estimates. The U.S. Food and Drug Administration’s Center for Food Safety and Applied Nutrition has estimated a consumption rate of 37 ng/day for butylparaben. Differences in daily exposure may be due to environmental factors. Environmental factors could include differences in climate, socioeconomic, cultural, or demographic factors. These factors can change the amount of paraben containing products used. It has been found that women have higher rates of parabens found in their blood, most likely due to the amount of paraben containing perosnal care products used daily. Exposure to parabens for pregnant women is of special concern due to the possible negative effects to the unborn child.
2d. Metabolism of Parabens in Humans

Metabolism of parabens in the human body depends on the route of exposure. After oral exposure, the parabens travel to the gastrointestinal tract and blood where they are rapidly absorbed. It is thought that parabens are broken down by esterase, leading to hydrolysis; p-hydroxybenzoic acid (PHBA) is the main product that results from hydrolysis of parabens. The metabolized parabens are then excreted in urine and feces. The body excretes a majority of orally ingested parabens within the twenty-four hours following exposure. Dermal exposure also results in absorption into the blood stream and metabolism by esterase. Increased chain length of the paraben decreases the ability of the paraben to penetrate the skin. However, the metabolic rate of parabens is based on the amount of paraben that penetrates the skin; for example, butylparaben is hydrolysed at a higher rate when compared to propylparaben. Oral and dermal exposures both lead to absorption in the blood as well as the liver. In the liver the parabens are adjoined with glycine, sulfate, or glucuronate, which aids in the breakdown of parabens for excretion in the urine. Parabens also have lipophilic characteristics that cause them to be absorbed and remain intact in human tissue. According to Aubert et al. results of a study on lab rats showed that 50% of dermally applied paraben was absorbed. The presence of intact parabens found in human excretions shows that they have escaped either skin or intestinal/liver metabolism.

Continuous dermal exposure to parabens may result in bioaccumulation according to a study by Ishiwatari et al. It has been shown that hydrolysis of parabens occurs more slowly in dermal exposure compared to exposure to the liver by route of ingestion. The slowed hydrolysis of dermally exposed parabens may be the reason for accumulation in the body. In comparison to oral and dermal absorption of parabens in the body, subcutaneous exposure creates a large exposure to parabens in the body due to the bypassing of hydrolysis in skin and gastrointestinal system. Figure 3, shows the different human exposure to parabens and how they are metabolized in the body. Human metabolism data are lacking, particularly showing the fraction of excreted paraben versus the fraction of excreted p-hydroxybenzoic acid; which would aid understanding the differences in metabolism by exposure route. However, it is known that most of a paraben is excreted in a conjugated form, with some amount of parabens being excreted in the free form.
2e. Endocrine System

The endocrine system controls many human bodily functions. The endocrine system produces hormones at various glands located in the body. The hormones then travel all over the body to maintain organs and tissues. The glands that release the hormones act as messengers to the receptors that collect and respond to the hormones. Reproduction, growth, sexual development, energy levels, bone and muscle strength, and homeostasis are some, but not all, of the areas that are governed by the endocrine system. The endocrine system has ten glands including: adrenal, hypothalamus, ovaries, pancreas, parathyroid, pineal, pituitary, testes, thymus, and thyroid gland. Hormones created in the endocrine system must find a compatible receptor in order to bind and carry out the instructions of the hormone. Hormones in reaction to a receptor can do one of two things, either alter an existing protein or turn on a gene to create a new protein. The main hormones of interest for this study were thyroid-stimulating hormone (TSH), Triiodothyronine (T3), and thyroxine (T4).
the human body, the pituitary gland creates thyroid-stimulating hormone (TSH), among other hormones, while T3 and T4 are created by the thyroid gland.

2f. Triiodothyronine (T3)

Triiodothyronine or T3 is created from a conversion of T4 in the blood. The lifespan of T3 is shorter than the lifespan of T4 to help ensure that T4 creates a steady flow of T3 in the body. The reference values of T3 are 80-190 ng/dL for those aged one or older.46 High levels of T3 can create rapid heart rate, insomnia, anxiety, as well as harm to the bones.47 For adults and children, T3 values greater than 180 ng/dL and greater than 200 ng/dL, respectively, are signs of hyperthyroidism. Hyperthyroidism should not be diagnosed using only a T3 test result, but a thyroid panel instead. Lower than average T3 levels could be due to a long-term illness, hypothyroidism, or starvation.

2g. Thyroxine (T4)

Thyroxine or T4 is created by the thyroid gland of the endocrine system. T4 tests are usually done on patients that may have hyper- or hypothyroidism or infertility problems. Some things may cause T4 levels to increase including, birth control, estrogens, methadone, tamoxifene, steroids, androgens, barbiturates, and lithium. A normal range of T4 is 4.5-11.2 mcg/dL.48 Results that are below the normal range could be caused by many things, including hypothyroidism, long term illness, or malnutrition.

2h. Thyroid-Stimulating Hormone (TSH)

Thyroid-stimulating hormone also known as thyrotropin, is created by the pituitary gland, which is then sent to the thyroid gland in order to create T4 and T3. As shown in Figure 4, the pattern of release and flow for TSH, T3, and T4 is shown throughout the endocrine system. TSH is released in a diurnal pattern, which means that it is released daily with it active mainly in the daytime.49 The normal reference range for TSH usually depends on the health professional, but this study will use the American Association of Clinical Endocrinologists range of 0.2-3.0 mIU/L.50 TSH values below the normal range could be due to hyperthyroidism, Graves’ disease, goiter, pituitary damage, or taking thyroid medication. It is important to note that the normal range for thyroid test results for pregnant women should follow trimester specific ranges (shown in Table 2).
2i. Endocrine Disruption

Endocrine disruption occurs when a body is exposed to a chemical, either natural or man-made, which in turn causes interference with the body’s normal endocrine system functioning, producing adverse effects. Chemicals that disrupt the endocrine system are called, endocrine-disrupting compounds (EDC). It is important to note that some endocrine disruptors may be naturally present in food as phytoestrogens. There are many definitions of endocrine-disrupting compounds.

The EPA has defined EDC as, …exogenous agents that interfere with the production, release, transport, metabolism, binding, action, or elimination of the natural hormones in the body responsible for the maintenance of homeostasis and the regulation of developmental processes.

Estrogens, either natural or chemically derived, are known to increase T4-binding globulin (TBG), which in turn increases total T4 concentrations. This increase of T4 is thought to make the endocrine system unstable, which may lead to endocrine disruption. Endocrine disruption can occur...
one of four ways. First, the chemical can simulate a hormone, which confuses the body into over-responding to the stimulus. Second, the chemical can imitate the hormone and cause it to respond at incorrect times. Third, the chemical can block the receptors of a hormone. Finally, the chemical can over or under produce hormones to stimulate or hinder the system. Endocrine disruptors are thought to be able to bind to the estrogen receptor, which would affect the estrogen-dependent genes. Another option is that parabens are similar structurally to xenobiotics, thus the estrogenicity of parabens may be a result of suppression of estrogen sulfotransferases (SULTs). Taxvig et al, believes that parabens interfere with the transport of cholesterol to the mitochondria, which would thereby interfere with steroidogenesis.

It is important to note that some pharmaceuticals purposely create endocrine disrupting effects, such as birth control pills. Following the passing of the Food Quality Protection Act and the Safe Drinking Water Act in 1996, the EPA began screening chemicals for endocrine disruption capabilities under the Endocrine Disruptor Screening Program (EDSP). A lack of regulation for parabens and other potential endocrine disrupting compounds has led to many in vivo and in vitro studies to examine the estrogenic effects of parabens (see table 3 in appendices).

2j. Estrogenic Effects of Parabens

It has been theorized that butylparaben possesses weak estrogenic effects when exposed subcutaneously, while another study found negative fertility effects from oral exposure to butyl- and propylparaben. When the latter study was repeated with a larger study design, no effect was found. Another rodent development study found that butylparaben did not affect development of rodent fetuses in any aspect, which led to the finding that butylparaben does not have a strong estrogenic effect on development. Some may argue that the estrogenic effects found in rodent studies cannot be extrapolated to humans. A study conducted on humans, dermally exposed 2.0% butylparaben on the whole body for two weeks did not have a reproductive effect. Another important study using fertility clinic data showed no evidence for a relationship between methyl-, propyl-, or butylparaben and altered hormone levels or sperm quality; however, it was found that butylparaben has greater reproductive toxicity potential. A nationally representative data study showed ethyl- and butylparaben to decrease thyroid hormone levels in females but not males.

It is thought that disease of the thyroid gland is related to breast cancer, however this has not been proven. Some studies have found parabens in breast cancer tissue and try to link parabens to breast cancer. However, there is no scientific basis for hypothesizing that parabens are linked to the development of breast cancer. Over recent decades an increase of breast cancer incidence has been correlated with the growth of personal care product use in the Western world, however it is important to note that other lifestyle changes have occurred during this time that could possibly confound correlation results. Another difficulty in establishing causation of parabens is that the harm or adverse effects may not come until many years after exposure.
Table 3 in the appendices, shows the various studies that have shown estrogenic effects from butylparaben, adapted from P.W. Harvey and D.J. Everett. According to Scialli, A. (2011) the studies each have limitations that make them unsupported, outlined in his paper. While the debate of the estrogenic effects of parabens continues, some people have disputed the possible additive or synergistic effect of multiple weak estrogenic compounds. However it has been found that compounds that are considered reproductive toxins have an adversity threshold, which would limit the additive or synergistic effects of multiple parabens. The long-term effects of low-level paraben exposure on the human body have not been studied and therefore are unknown. A need for further research on paraben human exposure is important to further understand paraben potency.

2k. Smoking

Smoking cigarettes has been shown to have a weak stimulatory effect on thyroid function and size. Although the mechanism is unknown, it is thought that the nicotine included in tobacco products causes a stimulatory effect of the nervous system, which in turn increases thyroid secretion. Some studies have found TSH levels are lower in those who are smokers. Various studies have shown differing results for specific thyroid levels. For thyroxine (T4), cigarette smoking was shown to slightly elevate T4 levels or create no change in T4 levels. For Triiodothyronine (T4), cigarette smoking was shown to increase T3 levels or create no change in T3 levels. Cigarette smoking was shown to decrease TSH levels or remain unaltered. It is important to note that my study looked at ever smoked data instead of current smoking data.
Chapter III
Methodology

3a. Data Source

Data used in these analyses were collected from the 2007-2008 National Health and Nutrition Examination Survey (NHANES).\textsuperscript{76} NHANES is conducted by the Center for Disease Control and Prevention (CDC) as an ongoing, cross-sectional study on the health and nutrition of adults and children in the United States. Participants of NHANES are selected by stratified multistage probability sampling of the civilian non-institutionalized population of the United States.\textsuperscript{77} The first stage of the multistage probability sampling of NHANES began with primary sampling units (PSUs), which were usually counties or small groups of adjacent counties. The PSUs were selected with probabilities proportionate to size. During the second stage, blocks or groups of blocks were selected within the PSUs. For the third stage, selections of dwelling units within the census blocks were chosen. During the fourth and final stage, a group of individuals were chosen from the sampled households to complete the household interview.\textsuperscript{78} Survey information was collected through household interviews by trained interviewers. Physical examinations, laboratory tests, and other measurements were completed in mobile examination centers.

3b. Study Population

Of the 10,149 participants of the 2007-2008 NHANES data collection, 2,718 participants were chosen to be included in the one-third subsample of paraben testing. This subsample included 114 participants with missing butylparaben data. Analyses were restricted to females 12 and over who were not pregnant, not taking birth control, and did not have thyroid problems, totaling to 897 participants. A total of 957 men, 622 females under 12 years of age, 64 women taking birth control, 20 pregnant women, 158 women with thyroid problems, and 6 with outlying values were excluded. Figure 5 goes into more detail for inclusion and exclusion criteria in a flow chart.
Figure 5. Inclusion and Exclusion Subsample Flow Chart

2,718 Environmental Phenols Subsample

957 Males Excluded

1,761 Females Only

622 Females Under 12 Years of Age Excluded

1,139 Females Over 12 Years of Age

158 Women with Thyroid Problems Excluded

20 Pregnant Women Excluded

64 Women Taking Birth Control Excluded

6 Females with Outlying Values Excluded

891 Females Over 12 Years of Age (are not pregnant, not taking birth control, and do not have thyroid problems)

58 Adults (20+) with Missing Data Excluded

19 Adolescents (12-19) with Missing Thyroid Data Excluded

14 Adolescents (12-19) with Missing Smoking Data Excluded

800 Females Over 12 Years of Age (are not pregnant, not taking birth control, do not have thyroid problems, and do not have missing data)

663 Adults (20+)

137 Adolescents (12-19)
3c. Butylparaben and Serum Thyroid Measures

Butylparaben and serum thyroid measures were measured in a one-third subsample of the dataset. Subsamples were done to prevent participant burnout. Mobile examination centers were used to collect examination and laboratory data. Butylparaben measures were collected from participants 6 and over using spot urine samples that were stored at -20°C until analysis. Hydrolysis of the conjugated specimen using β-glucuronidase/sulfatase, was followed by solid phase extraction (SPE), reverse-phase high-performance liquid chromatography separation, and atmospheric pressure chemical ionization-isotope dilution and tandem mass spectrometry (MS/MS). These measure methods are more fully described in a previous study. The limit of detection (LOD) for butylparaben was 0.2 ug/L. Serum thyroid measures were collected from participants 12 years and over from the NHANES thyroid profile. The serum samples were measured with immunoenzymatic assays.

3d. Data Analysis Overview

Data analyses were performed using SAS software (version 9.2; SAS Institute, Cary, NC). SAS survey procedures were employed to account for the complex, multistage study design of NHANES. Results presented are weighted except where noted otherwise. Descriptive statistics were obtained to summarize the distribution of study variables. Butylparaben and TSH were non-normally distributed for both the adolescent and adult age groups and was log transformed. Concentrations of butylparaben that were below the LOD (limit of detection) were replaced in the NHANES dataset with values equal to the LOD divided by the square root of two. Weighted means were obtained for the main independent and dependent variables of interest stratified by race/ethnicity group and by smoking status. Independent samples t-test and ANOVA was used to test whether butylparaben, TSH, T3, or T4 levels differed across race or smoking status groups. Weighted bivariate linear regression was performed for each independent variable with the dependent variable. Weighted multiple linear regressions were performed and parameter estimates with 95% confidence intervals were used to ascertain the relative measure of effect. Separate regression models stratified by age group were ran for each dependent variable (TSH, T3, and T4) regressed on butylparaben level and covariates, race and smoking status. An alpha=0.05 was used to determine statistical significance.
Chapter IV
Results

4a. Sample Demographics

The sample of females 12 years old and over totaled to 891 participants after exclusionary criteria were applied. Thirty-three adolescents (12-19 years old) were omitted from the analytic sample due to missing data on the variables, while 58 adults (20+ years old) were excluded due to missing values. The final study analytic data consisted of 800 participants, with 663 in the adult (20+years old) age group and 137 in the adolescent (12-19 years old) age group.

All analyses were done with stratified age groups and all results will be shown stratified. The participants ranged in age from 12 to 80 with a mean age 43.79 (SD=20.29) for the total subsample. The average age for adolescents was 15 (SD=2.14) while the average age for adults was 50 (SD=16.71). Table 4 describes the racial/ethnic distribution of adolescent and adults females.

Table 1: Distribution of Race/Ethnicity in Adolescent and Adult Female Study Subsamples

<table>
<thead>
<tr>
<th></th>
<th>Adolescent Females N (%)</th>
<th>Adult Females N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mexican American</td>
<td>39 (25.83)</td>
<td>132 (19.91)</td>
</tr>
<tr>
<td>Other Hispanic</td>
<td>27 (17.88)</td>
<td>86 (12.97)</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>37 (24.50)</td>
<td>282 (42.53)</td>
</tr>
<tr>
<td>Non-Hispanic Black</td>
<td>43 (28.48)</td>
<td>137 (20.66)</td>
</tr>
<tr>
<td>Other Race- Including Multi-Racial</td>
<td>5 (3.31)</td>
<td>26 (3.92)</td>
</tr>
</tbody>
</table>

*a Unweighted Estimates of Race/Ethnicity

Table 2: Distribution of Race/Ethnicity in Butylparaben and Thyroid Hormone Subgroups Among Adolescent and Adult Female Study Subsamples

<table>
<thead>
<tr>
<th></th>
<th>Adolescent Females N (%)</th>
<th>Adult Females N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Butylparaben:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexican American</td>
<td>43 (25.29)</td>
<td>139 (19.28)</td>
</tr>
<tr>
<td>Other Hispanic</td>
<td>28 (16.47)</td>
<td>88 (12.21)</td>
</tr>
<tr>
<td>Non-Hispanic Black</td>
<td>41 (24.12)</td>
<td>294 (40.78)</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>53 (31.18)</td>
<td>171 (23.72)</td>
</tr>
<tr>
<td>Other Race-Including Multi-Racial</td>
<td>5 (2.94)</td>
<td>29 (4.01)</td>
</tr>
<tr>
<td>TSH, T3, T4:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexican American</td>
<td>39 (25.83)</td>
<td>132 (19.91)</td>
</tr>
<tr>
<td>Other Hispanic</td>
<td>27 (17.88)</td>
<td>86 (12.97)</td>
</tr>
<tr>
<td>Non-Hispanic Black</td>
<td>37 (24.50)</td>
<td>282 (42.53)</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>43 (28.48)</td>
<td>137 (20.66)</td>
</tr>
<tr>
<td>Other Race-Including Multi-Racial</td>
<td>5 (3.31)</td>
<td>26 (3.93)</td>
</tr>
</tbody>
</table>

*a Unweighted Estimates of Race/Ethnicity
4b. Descriptive Statistics

As shown in Table 3, weighted means concentrations of ng/ml butylparaben, mIU/L TSH, ng/dL T3, and ug/dL T4 levels are shown with comparison between age and race. Among adolescent females, Mexican Americans had the highest mean concentration levels of butylparaben, T3, and T4. Other Hispanic Adolescents had the lowest mean concentration levels of butylparaben and T3. Non-Hispanic White adolescents had the highest mean concentration levels of TSH and the lowest mean concentration levels of T4, whereas the other race group, which includes multi-racial races, had the lowest mean concentration levels for TSH.

Adult female non-Hispanic Whites had the highest mean concentrations of butylparaben and TSH, while the other race group, which includes multi-racial races, had the lowest mean concentration levels of butylparaben and non-Hispanic Blacks had the lowest mean concentration levels of TSH. Adult Mexican Americans had the highest mean concentration levels of T3 and T4, whereas other race adult females, which include multi-racial races, had the lowest mean concentration levels of T3 and T4 mean levels.

The age stratified, weighted mean concentrations for TSH (mIU/L), T3 (ng/dL), and T4 (ug/dL) between adolescents who ever smoked and those who did not as well as adults who have smoked at least 100 cigarettes and those who have not are presented in Table 4.

### Table 3: Weighted Means of Butylparaben, TSH, T3, and T4 for Adolescent and Adult Females by Race/Ethnicity Groups

<table>
<thead>
<tr>
<th>Race/Ethnicity Groups</th>
<th>Butylparaben (log ng/ml)</th>
<th>TSH (log mIU/L)</th>
<th>T3 (ng/dL)</th>
<th>T4 (ug/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adolescent Females (12-19)</strong></td>
<td>0.25 (0.10-0.65)</td>
<td>2.06 (1.54-2.75)</td>
<td>121.65 (117.28-126.01)</td>
<td>7.44 (7.25-7.62)</td>
</tr>
<tr>
<td>Mexican American</td>
<td>0.96 (0.14-6.43)</td>
<td>1.71 (1.20-2.43)</td>
<td>130.16 (115.28-145.04)</td>
<td>8.19 (7.65-8.74)</td>
</tr>
<tr>
<td>Other Hispanic</td>
<td>0.08 (0.03-0.28)</td>
<td>1.60 (0.79-3.25)</td>
<td>125.51 (116.57-134.46)</td>
<td>7.67 (7.37-7.98)</td>
</tr>
<tr>
<td>Non-Hispanic Black</td>
<td>0.19 (0.05-0.65)</td>
<td>2.80 (2.15-3.63)</td>
<td>121.24 (115.48-126.99)</td>
<td>7.12 (6.93-7.31)</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>0.28 (0.15-0.49)</td>
<td>1.49 (1.10-2.02)</td>
<td>116.74 (111.86-121.62)</td>
<td>7.64 (7.36-7.91)</td>
</tr>
<tr>
<td>Other Race- Including Multi-Racial</td>
<td>1.61 (0.14-18.2)</td>
<td>0.45 (0.06-3.31)</td>
<td>114.47 (98.14-130.79)</td>
<td>8.07 (7.50-8.65)</td>
</tr>
<tr>
<td><strong>Adult Females (20+)</strong></td>
<td>1.40 (0.98-2.00)</td>
<td>3.06 (2.39-3.91)</td>
<td>108.10 (105.19-111.01)</td>
<td>7.63 (7.43-7.82)</td>
</tr>
<tr>
<td>Mexican American</td>
<td>0.61 (0.30-1.24)</td>
<td>3.15 (2.29-4.33)</td>
<td>113.46 (108.01-118.91)</td>
<td>8.11 (7.81-8.41)</td>
</tr>
<tr>
<td>Other Hispanic</td>
<td>2.57 (1.53-4.31)</td>
<td>2.90 (1.96-4.30)</td>
<td>112.64 (107.34-117.94)</td>
<td>7.92 (7.42-8.43)</td>
</tr>
<tr>
<td>Non-Hispanic Black</td>
<td>1.78 (1.01-3.13)</td>
<td>3.39 (2.52-4.57)</td>
<td>107.01 (103.06-110.97)</td>
<td>7.52 (7.25-7.78)</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>0.51 (0.23-1.17)</td>
<td>1.85 (1.62-2.11)</td>
<td>109.16 (104.22-114.10)</td>
<td>7.75 (7.50-8.01)</td>
</tr>
<tr>
<td>Other Race- Including Multi-Racial</td>
<td>1.33 (0.16-11.2)</td>
<td>2.62 (1.06-6.47)</td>
<td>106.77 (99.62-113.95)</td>
<td>7.66 (7.24-8.08)</td>
</tr>
</tbody>
</table>
Table 4: Weighted Means of Butylparaben, TSH, T3, and T4 for Adolescent and Adults Female Smokers and Non-Smokers

<table>
<thead>
<tr>
<th></th>
<th>Adolescent Females (12-19)</th>
<th>Adult Females (20+)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Smoking (Yes)</td>
<td>Smoking (No)</td>
</tr>
<tr>
<td>TSH Mean [log mIU/L]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(95% CI)</td>
<td>2.61 (1.41-4.82)</td>
<td>1.95 (1.35-2.82)</td>
</tr>
<tr>
<td>T3 Mean [ng/dL]</td>
<td>121.77 (114.71-128.82)</td>
<td>122.51 (116.36-128.65)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>7.51 (7.11-7.92)</td>
<td>7.41 (7.13-7.69)</td>
</tr>
<tr>
<td>Butylparaben Mean [log ng/ml]</td>
<td>0.32 (0.12-0.89)</td>
<td>0.19 (0.09-0.44)</td>
</tr>
</tbody>
</table>

a Adolescent Smoking question: Have you ever smoked before?
b Adult Smoking question: Have you smoked at least 100 cigarettes in lifetime?

4c. Bivariate Analysis

Weighted bivariate regression analysis was performed for TSH, T3, and T4 separately for adolescent and adults females. Table 6, shows bivariate weighted regression coefficients with 95% confidence intervals. Among adult females, a one-ng/ml increase in butylparaben was associated with a -1.07 decrease ng/dL in T3 (p< .05). Among adult females, a one-ng/ml increase in butylparaben was associated with a -0.12 decrease ug/dL in T4 (p< .01). Butylparaben level was not predictive of TSH (p=. 15), T3 (p=. 79), or T4 (p=. 07) levels in adolescent females, whereas butylparaben levels in adult females was not predictive of TSH (p=. 55) levels.

Table 5: Weighted Regression of TSH, T3, and T4 on Butylparaben for Adolescent and Adult Females

<table>
<thead>
<tr>
<th></th>
<th>β (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Butylparaben (log ng/ml)</td>
<td></td>
</tr>
<tr>
<td>Adolescent Females (12-19)</td>
<td></td>
</tr>
<tr>
<td>TSH (log mIU/L)</td>
<td>-0.29 (-0.68-0.10)</td>
</tr>
<tr>
<td>T3 (ng/dL)</td>
<td>-0.00 (-0.01-0.01)</td>
</tr>
<tr>
<td>T4 (ug/dL)</td>
<td>0.24 (-0.01-0.50)</td>
</tr>
<tr>
<td>Adult Females (20+)</td>
<td></td>
</tr>
<tr>
<td>TSH (log mIU/L)</td>
<td>-0.05 (-0.24-0.13)</td>
</tr>
<tr>
<td>T3 (ng/dL)</td>
<td>-1.05 (-2.05- -0.04)*</td>
</tr>
<tr>
<td>T4 (ug/dL)</td>
<td>-0.20 (-0.30- -0.09)**</td>
</tr>
</tbody>
</table>

*p< .05
**p< .01
4d. Multivariate Analysis
Six multiple regression analyses were performed. Butylparaben was the exposure variable, and TSH, T3, and T4 were the outcome variables, with smoking and race as controlling variables. The multiple regression analyses were performed separately for adolescent females (12-19) and adult females (20+). Results of the multivariate regressions stratified by age group are presented in Tables 6-8.

4d1. Thyroid Stimulating Hormone (TSH)
a. Adolescent Females (12-19 years)
TSH levels for Other Hispanic adolescent females had 0.3 mIU/L higher than the average of all racial/ethnic groups, adjusting for butylparaben, smoking, and race (p<.05). Butylparaben (p=.10) and smoking (p=.40) were not associated with TSH level change. Mexican American (p=.57), non-Hispanic White (p=.59) and non-Hispanic Black (p=.48) race/ethnicities were not associated with TSH level changes among adolescent females.

b. Adult Females (20+ years)
TSH levels for Mexican American adult females were 0.17mIU/L lower than the average of all racial/ethnic groups, adjusting for butylparaben, smoking, and race (p<.01). TSH levels for other Hispanic adult females were 0.12mIU/L higher than the average of all racial/ethnic groups, adjusting for butylparaben, smoking, and race (p<.05). Butylparaben (p=.30) and smoking (p=.07) were not associated with TSH level change. Non-Hispanic White (p=.79) and non-Hispanic Black (p=.41) race/ethnicities were not associated with TSH level changes among adult females.

Table 6: Weighted Regression of TSH (log mIU/L) on Butylparaben (log ng/ml) and Covariates

<table>
<thead>
<tr>
<th>Independent Variables</th>
<th>Adolescent Females (12-19)</th>
<th>Adult Females (20+)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=137</td>
<td>N=663</td>
</tr>
<tr>
<td>Butylparaben</td>
<td>-0.05 (-0.10-0.01)</td>
<td>-0.01 (-0.04-0.01)</td>
</tr>
<tr>
<td>Smoking</td>
<td>0.14 (-0.20-0.47)</td>
<td>-0.14 (-0.30-0.01)</td>
</tr>
<tr>
<td>Mexican American</td>
<td>0.07 (-0.17-0.30)</td>
<td>-0.17 (-0.26- -0.07)**</td>
</tr>
<tr>
<td>Other Hispanic</td>
<td>0.30 (0.03-0.57)*</td>
<td>0.12 (0.00-0.24)*</td>
</tr>
<tr>
<td>Non-Hispanic Black</td>
<td>0.06 (-0.19-0.32)</td>
<td>0.02 (-0.16-0.20)</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>0.09 (-0.18-0.36)</td>
<td>0.05 (-0.07-0.17)</td>
</tr>
<tr>
<td>(F)</td>
<td>7.46</td>
<td>7.25</td>
</tr>
<tr>
<td>df</td>
<td>6, 16</td>
<td>6, 16</td>
</tr>
<tr>
<td>(R^2) (adjusted (R^2))</td>
<td>0.12 (0.11)</td>
<td>0.025 (0.022)</td>
</tr>
<tr>
<td>(p)</td>
<td>&lt; .0001*</td>
<td>&lt; .0001*</td>
</tr>
</tbody>
</table>

*p<.05
4d2. Triiodothyronine (T3)

a. Adolescent Females (12-19 years)

None of the covariates in the model significantly changed T3 levels. Butylparaben (p=. 66), smoking (p=. 83), Mexican American (p=. 12), other Hispanic (p=. 74), non-Hispanic White (p=. 39), and non-Hispanic Black (p=. 83) races/ethnicities were not associated with changes in T3 levels among adolescent females.

b. Adult Females (20+ years)

T3 levels for other Hispanic adult females were 0.03 ng/dL lower than the average of all racial/ethnic groups, adjusting for butylparaben, smoking, and race (p<. 05). Butylparaben (p=. 12), smoking (p=. 16), Mexican American (p=. 54), non-Hispanic White (p=. 12), and non-Hispanic Black (p=. 16) races/ethnicities were not associated with change in T3 levels among adult females.

Table 7: Weighted Regression of T3 (ng/dL) on Butylparaben (log ng/ml) and Covariates

<table>
<thead>
<tr>
<th>Independent Variables</th>
<th>Adolescent Females (12-19) N=137</th>
<th>Adult Females (20+) N=663</th>
<th>β (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Butylparaben</td>
<td>-0.51 (-2.88-1.86)</td>
<td>-0.01 (-0.02-0.00)</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>-1.03 (-10.99-8.94)</td>
<td>0.04 (-0.02-0.09)</td>
<td></td>
</tr>
<tr>
<td>Mexican American</td>
<td>-6.14 (-14.15-1.88)</td>
<td>-0.01 (-0.06-0.03)</td>
<td></td>
</tr>
<tr>
<td>Other Hispanic</td>
<td>-1.12 (-8.08-5.84)</td>
<td>-0.03 (-0.06- -0.00)*</td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic Black</td>
<td>3.74 (-5.32-12.80)</td>
<td>0.03 (-0.01-0.07)</td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>9.49 (-10.99-8.94)</td>
<td>0.03 (-0.01-0.07)</td>
<td></td>
</tr>
</tbody>
</table>

|            |                          |                          |          |
| F          | 2.64                     | 8.08                     |          |
| df         | 6, 16                    | 6, 16                    |          |
| R² (adjusted R²) | 0.05 (0.03)             | 0.028 (0.025)            |          |
| p          | 0.0165*                  | <. 0001*                 |          |

*p<. 05
4d3. Thyroxine (T4)

a. Adolescent Females (12-19 years)

T4 levels for other Hispanic adolescent females were 0.67 ug/dL lower than the average of all racial/ethnic groups, adjusting for butylparaben, smoking, and race (p<. 0001). T4 levels for Non-Hispanic White adolescent females were 0.44 ug/dL higher than the average of all racial/ethnic groups, adjusting for butylparaben, smoking, and race (p<. 05). Butylparaben (p=. 18), smoking (p=. 84), Mexican American (p=. 34), and non-Hispanic Black (p=. 77) racial/ethnic groups were not associated with change in T4 levels among adolescent females.

b. Adult Females (20+ years)

Adult female T4 levels were 0.12 ug/dL lower than average with increased butylparaben exposure, adjusting for butylparaben, smoking, and race (p<. 01). Smoking (p=. 51), Mexican American (p=. 47), non-Hispanic Black (p=. 05), and non-Hispanic White (p=. 40) racial/ethnic groups were not associated with change in T4 levels among adolescent females.

Table 8: Weighted Regression of T4 (ug/dL) on Butylparaben (log ng/ml) and Covariates

<table>
<thead>
<tr>
<th>Independent Variables</th>
<th>Adolescent Females (12-19)</th>
<th>Adult Females (20+)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (95%C1)</td>
<td></td>
</tr>
<tr>
<td>Butylparaben</td>
<td>0.13 (-0.07-0.33)</td>
<td>-0.12 (-0.19- -0.05)**</td>
</tr>
<tr>
<td>Smoking</td>
<td>0.07 (-0.60-0.74)</td>
<td>-0.07 (-0.29-0.15)</td>
</tr>
<tr>
<td>Mexican American</td>
<td>-0.14 (-0.45-0.16)</td>
<td>-0.08 (-0.30-0.14)</td>
</tr>
<tr>
<td>Other Hispanic</td>
<td>-0.67 (-0.93 -0.42)**</td>
<td>-0.24 (-0.50-0.02)</td>
</tr>
<tr>
<td>Non-Hispanic Black</td>
<td>0.06 (-0.39-0.52)</td>
<td>0.17 (-0.24-0.57)</td>
</tr>
<tr>
<td>Non-Hispanic White</td>
<td>0.44 (0.07-0.81)*</td>
<td>0.28 (-0.01-0.57)</td>
</tr>
<tr>
<td>F</td>
<td>9.09</td>
<td>10.52</td>
</tr>
<tr>
<td>df</td>
<td>6, 16</td>
<td>6, 16</td>
</tr>
<tr>
<td>R² (adjusted R²)</td>
<td>0.15 (0.13)</td>
<td>0.04 (0.03)</td>
</tr>
<tr>
<td>p</td>
<td>&lt;.0001*</td>
<td>&lt;.0001*</td>
</tr>
</tbody>
</table>

*p<. 05
**p<. 01
***p<.0001
Chapter V
Discussion and Conclusion

In this analysis of data from 2007-2008 NHANES exposure to butylparaben and hormone levels (TSH, T3, and T4), bivariate results among adult females found that, butylparaben was associated with decreases in T3 among adult females, but not associated with change in T3 among adolescent females. Butylparaben was associated with decreases in T4 among adult females, but was not associated with change in T4 among adolescent females. No association was found for TSH change from increased butylparaben levels in adolescent or adult females. Multivariate results show butylparaben associated with a decrease in T4 levels among adult females but not with adolescent females, adjusting for race and smoking. Butylparaben was not associated with increased TSH or T3 levels for adolescent or adult females. TSH levels for Mexican American adult females were higher than the average of all racial/ethnic groups, adjusting for butylparaben, smoking, and race. TSH levels for other Hispanic adolescent females were higher than the average of all racial/ethnic groups, adjusting for butylparaben, smoking, and race. T3 and T4 levels for other Hispanic adolescent females were lower than the average of all racial/ethnic groups, adjusting for butylparaben, smoking, and race. T4 levels for Non-Hispanic White adolescent and adult females were higher than the average of all racial/ethnic groups, adjusting for butylparaben, smoking, and race. Smoking and non-Hispanic Black race/ethnicity was not associated with changes in thyroid levels in any multivariate model. The adolescent female group for this study showed differing results to adult females. Among adolescent and adult females butylparaben, TSH, T3, and T4 variation was found among the race classifications. Smoking did not present an association to any of the thyroid hormone levels in adolescent or adult females. Though smoking did not show an association in either of the age groups, we did find weighted mean differences for TSH, T3, T4, and butylparaben among those who smoked and those who did not smoke as mentioned previously in the descriptive statistics section of the results.

To the best of my knowledge, two studies have been done to which I could compare some of my findings. Koepp et al. studied the association of urinary triclosan and paraben concentrations with serum thyroid measures using the same NHANES 2007-2008. His study included both males and females, and the use of paraben measures adjusted for creatinine in analyses. Calafat et al. studied paraben concentrations in NHANES 2005-2006. Koepp et al. and Calafat et al. did not calculate geometric means of butylparaben due to high percentages of values below the LOD, while Calafat et al. did not conduct multivariate analysis due to high percentage of values below the LOD. The large amount of values below the LOD in my study may have created misrepresented means for butylparaben. The only study to which I can compare my multivariate results is from Koepp et al. The final regression models of Koepp et al. included covariates, age, sex, BMI, and urinary creatinine. My study did not examine BMI or urinary creatinine. Creatinine levels are used to measure kidney function, and it was not clear why these measures were included in the analyses of Koepp et al. study. Among adolescents and adults of both genders, the study found no significant
associations for T3 and T4 levels with increased levels of butylparaben. Among adolescent females no significant associations were found for T3 and T4 levels with increased butylparaben levels. Among adult females, evidence of an inverse association for ln-Free T3 levels with increased butylparaben levels.\textsuperscript{10} My study used total T3 and T4, whereas, Koeppel et al. study used both free and total T3 and T4. Lack of comparison between studies is due to differences in variables and models used for analyses.

Hollowell et al. studied serum TSH, T4, and thyroid antibodies from 1988 to 1994 in the NHANES III survey. This study found that TSH level among non-Hispanic blacks was lower than that of non-Hispanic whites, as well as T4 levels among Mexican Americans being higher than that of non-Hispanic Whites.\textsuperscript{31} Hollowell et al. believed that environmental factors, such as, region, poverty status, and urban versus rural residence, may have been playing a role in differences between racial/ethnic groups.\textsuperscript{29} Differences in race/ethnic thyroid levels may also be due to the cultural differences between race/ethnic groups, such as behaviors, beliefs, or traditions. My study also found many race/ethnic groups associated with changes in thyroid hormone levels. It is unclear why race is associated with changes in thyroid levels. A study by McLeod examining thyroid-related disease among U.S. military personnel from 1997 to 2011, found thyroid levels varied across race groups. McLeod was uncertain on whether the racial differences were caused by genetics, environmental exposure, or a combination of both.\textsuperscript{81} Future analyses should account for environmental factors such as region, poverty status, SES, urban vs. rural location, as well as cultural differences.

Meeker et al. studied urinary concentrations of parabens and serum hormone levels, semen quality parameters, and sperm damage from fertility clinic data. They found no evidence for an association between parabens (methylparaben, propylparaben, and butylparaben) with altered hormone levels or semen quality parameters.\textsuperscript{11} They also found that increased levels of butylparaben were associated with sperm DNA damage. BMI of participants was associated with higher levels of parabens concentrations, possibly due to an increase to exposure.

While few human studies have found associations for change in thyroid hormone levels from increased levels of butylparaben\textsuperscript{10}, several rodent studies have found associations for estrogenic effects of increased butylparaben.\textsuperscript{4, 6, 19, 54} Rodent effects of butylparaben exposure included birth defects, uterotrophic capacity, reproductive toxicity, and developmental toxicity. A list of studies finding estrogenic effects from butylparaben exposure can be found in the appendices. A rodent study by Daston, found no effects of butylparaben on development, while it did produce maternal toxicity in rats at exposure doses up to 1000mg/kg/day.\textsuperscript{56} A rodent study by Hossaini et al. found a lack of estrogenic effects from butylparaben exposure to mice.\textsuperscript{21} Conflicting results can be seen among rodent studies, some find estrogenic effects while others find a lack of estrogenic effects. It is important to look at if/how the rodent study results could be applied to humans. Some may argue that the estrogenic effects found in rodent studies cannot be extrapolated to humans.\textsuperscript{57}
5a. Strengths

The use of a nationally representative study increases the generalizability of the results. To my knowledge, this is the first study to investigate butylparaben level associated with thyroid hormone levels (TSH, T3, T4) in a female only study design. Exclusion of pregnant women, women taking birth control, as well as women with thyroid problems help to limit confounding effects of known thyroid increasing properties. Stratifying analyses by age groups, adolescent’s age 12 to 19 years and adults age 20 years and over helped to reduce bias due to differing thyroid activity in younger and older ages.

5b. Limitations

The lack of associations in the adolescent female age group may have been due to the smaller sample size. The adolescent female sample size was only 151 whereas the adult female sample size was much large at 663. It is also possible that adolescents excrete lower levels of thyroid hormones and are therefore more difficult to detect associations in thyroid levels. Among adolescent females 66 (39%) participants had butylparaben levels below the limit of detection (LOD), while adults had 256 (36%) participants with butylparaben levels below the LOD. As described in the methodology section butylparaben levels below the LOD would be replaced with the LOD divided by the square root of two (0.14). For both adolescent and adult females, butylparaben levels below the LOD made up the largest percentages of values; this may have been the reason for the skewness of the butylparaben variable. Causation cannot be established due to the use of data from NHANES, an observational, cross-sectional study. Butylparaben was measured using a spot urine test. Parabens are known to have a short half-life, however three recent studies show that timing of the urine spot test do not affect the accuracy of paraben representation. 41, 82, 83

5c. Future Study

It is still debated whether parabens are endocrine/thyroid disruptors. As of now, parabens are not considered endocrine disruptors, yet some studies have shown associations of parabens with changes in thyroid hormone levels. Studies are needed that explain the absorption and metabolism of parabens and their effects or lack of effects on thyroid hormone levels. Previous studies researching these topics have only been done in rodent populations (see table 3 in appendices). As mentioned earlier multiple parabens are usually used products and thus research needs to be done to show the effects of the combined parabens on thyroid hormone levels. Case-control studies could be used to study the possible synergistic effects of parabens on the human body. Cohort studies would be useful in studying the long-term effects of parabens on the human body. It is unclear why race is associated with increases and decreases of butylparaben, TSH, T3, and T4 levels. Future study on racial effects of parabens on thyroid hormone levels is needed to better understand the differences between races.
A randomized controlled study (RCT) could be used to study the cause of thyroid differences in race/ethnicities.

5d. Conclusion

In conclusion, the present analysis examined the relationship between butylparaben and thyroid hormone levels among a female only study design using a large, representative sample of the U.S. adolescent and adult female population. NHANES data from 814 females aged 12 and over who were not pregnant, not taking birth control, and did not have thyroid problems increased the generalizability of findings. I observed significant association between butylparaben and decreases in T4 thyroid hormone levels among adult females, as well as several associations both positive and negative between race categories and thyroid hormone levels in adolescent and adult females. While parabens are currently not considered endocrine disruptors, the human metabolism of and affects from exposure to parabens are not well understood. Results from this study showed decreased levels of T4 thyroid hormone levels associated with increased levels of butylparaben, as well as differences in thyroid hormone levels among racial/ethnic groups. The results of this study indicating no statistically significant association between butylparaben and decreases in thyroid hormone levels are consistent with results of some rodent studies finding a lack of estrogenic effects of parabens. Although not many human studies have found significant results, some rodent studies have found paraben associations with adverse health effects. These results, in accordance with the in vitro and in vivo literature, suggest that butylparaben exposure may not be associated with altered thyroid hormone levels in humans. Additional human studies with paraben and thyroid hormone levels are needed to confirm these potential significant findings.
References


8. Gazin, V., Marsden, E., Briffaux, J. Propylparaben-8- week post-weaning juvenile toxicity study with a 26-week treatment-free period in the male Wistar rat by the oral route. US Society of Toxicology Meeting, 2012; Abstract No. 2359.


76. Centers for Disease Control and Prevention (CDC). National Health and Nutrition Examination Survey (2007-2008) – Demographics (DEMO_E), Environmental Phenols Subsample (EPH_E), Thyroid Profile (THYROD_E), Medical Conditions (MCQ_E), Reproductive Health (RHQ_E), and Smoking-Cigarette Use (SMQ_E) – Merged. [Data Sets].


# Appendices

## Table 9: Parabens and Synonymous Names

<table>
<thead>
<tr>
<th>Paraben Type</th>
<th>Common Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methylparaben</td>
<td>Benzoic Acid, 4-Hydroxy-, Methyl Ester</td>
</tr>
<tr>
<td></td>
<td>p-Carbomethoxyphenol</td>
</tr>
<tr>
<td></td>
<td>4-Hydroxybenzoic Acid, Methyl Ester</td>
</tr>
<tr>
<td></td>
<td>p-Methoxycarbonylphenol</td>
</tr>
<tr>
<td></td>
<td>Methyl 4-Hydroxybenzoate</td>
</tr>
<tr>
<td></td>
<td>Methyl p-hydroxybenzoate</td>
</tr>
<tr>
<td></td>
<td>Methyl Parahydroxybenzoate Ester</td>
</tr>
<tr>
<td></td>
<td>Parahydroxybenzoate Ester</td>
</tr>
<tr>
<td>Ethylparaben</td>
<td>Benzoic Acid, 4-Hydroxy-, Ethyl Ester</td>
</tr>
<tr>
<td></td>
<td>Ethyl p-hydroxy benzoate</td>
</tr>
<tr>
<td></td>
<td>Ethyl 4-Hydroxybenzoate</td>
</tr>
<tr>
<td></td>
<td>Ethyl p-Hydroxybenzoate</td>
</tr>
<tr>
<td></td>
<td>Ethyl Parahydroxybenzoate Ester</td>
</tr>
<tr>
<td></td>
<td>4-Hydroxybenzoic Acid, Ethyl Ester</td>
</tr>
<tr>
<td></td>
<td>Parahydroxybenzoate Ester</td>
</tr>
<tr>
<td>Propylparaben</td>
<td>Benzoic Acid, 4-Hydroxy-, Propyl Ester</td>
</tr>
<tr>
<td></td>
<td>4-Hydroxybenzoic Acid, Propyl Ester</td>
</tr>
<tr>
<td></td>
<td>Parahydroxybenzoate Ester</td>
</tr>
<tr>
<td></td>
<td>Propyl p-hydroxybenzoate</td>
</tr>
<tr>
<td></td>
<td>Propyl 4-Hydroxybenzoate</td>
</tr>
<tr>
<td></td>
<td>Propyl p-Hydroxybenzoate</td>
</tr>
<tr>
<td></td>
<td>Propyl Parahydroxybenzoate Ester</td>
</tr>
<tr>
<td>Isopropylparaben</td>
<td>Benzoic Acid, 4-Hydroxy-, 1-Methylethyl Ester</td>
</tr>
<tr>
<td></td>
<td>p-Hydroxybenzoic Acid, Isopropyl Ester</td>
</tr>
<tr>
<td></td>
<td>4-Hydroxybenzoic Acid, 1-Methylethyl Ester</td>
</tr>
<tr>
<td></td>
<td>Isopropyl p-Hydroxybenzoate Ester</td>
</tr>
<tr>
<td></td>
<td>1-Methylethyl-4-Hydroxybenzoate Ester</td>
</tr>
<tr>
<td></td>
<td>Parahydroxybenzoic Acid, Isopropyl Ester</td>
</tr>
<tr>
<td>Butylparaben</td>
<td>Benzoic Acid, 4-Hydroxy-, Butyl Ester</td>
</tr>
<tr>
<td></td>
<td>Butyl 4-Hydroxybenzoate</td>
</tr>
<tr>
<td></td>
<td>Butyl p-Hydroxybenzoate</td>
</tr>
<tr>
<td></td>
<td>Butyl p-hydroxy benzoate</td>
</tr>
<tr>
<td></td>
<td>Butyl Parahydroxybenzoate Ester</td>
</tr>
<tr>
<td></td>
<td>Parahydroxybenzoate Ester</td>
</tr>
<tr>
<td>Isobutylparaben</td>
<td>Benzoic Acid, 4-Hydroxy-, 2-Methylpropyl Ester</td>
</tr>
<tr>
<td></td>
<td>4-Hydroxybenzoic Acid, 2-Methylpropyl Ester</td>
</tr>
<tr>
<td></td>
<td>Isobutyl p-Hydroxybenzoate Ester</td>
</tr>
<tr>
<td></td>
<td>Isobutyl Parahydroxybenzoate Ester</td>
</tr>
<tr>
<td></td>
<td>Parahydroxybenzoic Acid, Isobutyl Ester</td>
</tr>
<tr>
<td>Benzyllparaben</td>
<td>Benzoic Acid, 4-Hydroxy-, Phenylmethyl Ester</td>
</tr>
<tr>
<td></td>
<td>Benzyll p-Hydroxybenzoate</td>
</tr>
<tr>
<td></td>
<td>Benzyll Parahydroxybenzoate Ester</td>
</tr>
<tr>
<td></td>
<td>4-Hydroxybenzoic Acid, Benzyll Ester</td>
</tr>
<tr>
<td></td>
<td>Phenylmethyl 4-Hydroxybenzoate Ester</td>
</tr>
</tbody>
</table>
Table 10: Trimester Specific T3, T4, and TSH Hormone Ranges during Pregnancy

<table>
<thead>
<tr>
<th></th>
<th>First Trimester</th>
<th>Second Trimester</th>
<th>Third Trimester</th>
</tr>
</thead>
<tbody>
<tr>
<td>FT3 pmol/L</td>
<td>10-18</td>
<td>9-16</td>
<td>8-14</td>
</tr>
<tr>
<td>FT4 pmol/L</td>
<td>3.4-6.6</td>
<td>3.2-6.2</td>
<td>3.2-5.6</td>
</tr>
<tr>
<td>TSH mU/L</td>
<td>&lt;0.01-3.4</td>
<td>1.3-3.3</td>
<td>1.2-3.5</td>
</tr>
</tbody>
</table>
Table 11: Butylparaben Studies with Estrogenic Results

<table>
<thead>
<tr>
<th>Butylparaben</th>
<th>Result</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>In vivo (rat birth defects)</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>In vitro (yeast C receptor binding)</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>In vitro (human MCF7)*</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>In vitro (human MCF7)</td>
<td>58</td>
</tr>
<tr>
<td></td>
<td>In vitro (rat uterus receptor binding)</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>In vivo (rat uterotrophic)</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>In vivo (rat uterotrophic)</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>In vivo (rat reproductive toxicity)</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td>In vivo (mouse reproductive toxicity)</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>In vivo (rat development and reproductive toxicity)</td>
<td>61</td>
</tr>
<tr>
<td></td>
<td>In vivo (rat uterotrophic)</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>In vivo (mouse uterotrophic)</td>
<td>59</td>
</tr>
</tbody>
</table>

*MCF7 is a hormone-responsive breast cancer cell line*